Application of an Inter-Species Extrapolation Method for the Prediction of Drug Interactions between Propolis and Duloxetine in Humans
Open Access
- 9 March 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (5), 1862
- https://doi.org/10.3390/ijms21051862
Abstract
Duloxetine (DLX) is a potent drug investigated for the treatment of depression and urinary incontinence. DLX is extensively metabolized in the liver by two P450 isozymes, CYP2D6 and CYP1A2. Propolis (PPL) is one of the popular functional foods known to have effects on activities of CYPs, including CYP1A2. Due to the high probability of using DLX and PPL simultaneously, the present study was designed to investigate the potent effect of PPL on pharmacokinetics (PKs) of DLX after co-administration in humans. A PK study was first conducted in 18 rats (n = 6/group), in which the plasma concentration of DLX and its major metabolite 4-hydroxy duloxetine (4-HD) with or without administration of PPL was recorded. Population PKs and potential effects of PPL were then analyzed using NONMEM software. Lastly, these results were extrapolated from rats to humans using the allometric scaling and the liver blood flow method. PPL (15,000 mg/day) exerts a statistically significant increase in DLX exposures at steady state, with a 20.2% and 24.6% increase in DLX and the same 28.0% increase in DLX when DLX (40 or 60 mg) was administered once or twice daily, respectively. In conclusion, safety issues are required to be attended to when individuals simultaneously use DLX and PPL at high doses, and the possibility of interactions between DLX and PPL might be noted.
Keywords
Funding Information
- National Research Foundation of Korea (NRF- 2018R1C1B5085278)
This publication has 47 references indexed in Scilit:
- Pharmacokinetics and Safety of Duloxetine Enteric-coated Tablets in Chinese Healthy Volunteers: A Randomized, Open-label, Single- and Multiple-dose StudyClinical Psychopharmacology and Neuroscience, 2013
- Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug–drug interactionsXenobiotica, 2009
- Pharmacokinetics of Duloxetine in Breast Milk and Plasma of Healthy Postpartum WomenClinical Pharmacokinetics, 2008
- In Vitro and In Vivo Evaluations of Cytochrome P450 1A2 Interactions with DuloxetineClinical Pharmacokinetics, 2008
- Pharmacokinetics and Tolerability of??Duloxetine following Oral Administration to Healthy Chinese SubjectsClinical Pharmacokinetics, 2007
- Animal-to-Human Extrapolation of the Pharmacokinetic and Pharmacodynamic Properties of BuprenorphineClinical Pharmacokinetics, 2007
- Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted fromin-vivo rat data?European Journal of Drug Metabolism and Pharmacokinetics, 2004
- Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo CorrelationsClinical Pharmacokinetics, 1999
- Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1982
- Animal scale-upJournal of Pharmacokinetics and Biopharmaceutics, 1973